Tissue Regenix Group PLC - Leeds, England-based medical device company - Reports revenue of USD24.5 million for 2022, up 24% from USD19.7 million a year earlier. Particularly, BioRinse increased by 26% to USD16.0 million from USD12.7 million. Pretax loss narrows to USD2.8 million from USD5.1 million in 2021, as operating loss narrows to USD2.0 million from USD4.4 million. Declares no dividend for the year, unchanged from a year prior. Looking ahead, Tissue Regenix says it is well prepared for additional market fluctuations as markets continue to normalise post-pandemic.
Chair Jonathan Glenn says: "During what has been a year of immense progress with some notable milestones achieved, we have continued to demonstrate and realise operational and commercial growth."
Current stock price: 0.61 pence each, up 0.5% on Tuesday around noon in London
12-month change: up 56%
By Xindi Wei, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Tissue Regenix Group (TRX)